|
Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia.
|
Oct 2013
|
Am J Hematol
|
aplastic anemia
|
|
Prediction of adverse events during Intensive Induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes
|
Jan 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.
|
Oct 2013
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Myelodysplastic syndromes: Contemporary review and how we treat
|
Jan 2016
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes.
|
May 2013
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Calculator-free point-of-care prognostication in myelodysplastic syndromes.
|
Jan 2019
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival
|
Dec 2014
|
Am J Clin Pathol
|
myelodysplastic syndromes (MDS)
|
|
High levels of vascular endothelial growth factor protein expression are associated with an increased risk of transfusion dependence in myelodysplastic syndromes
|
Mar 2013
|
Am J Clin Pathol
|
myelodysplastic syndromes (MDS)
|
|
Quality of life and physicians' perception in myelodysplastic syndromes
|
May 2012
|
Am J Blood Res
|
myelodysplastic syndromes (MDS)
|
|
Costs and quality of life in patients with myelodysplastic syndromes.
|
Aug 2013
|
Am J Blood Res
|
myelodysplastic syndromes (MDS)
|
